ScoreWhy is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 21.25%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.70 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.80% of over the last 5 years
4
The company has declared Positive results for the last 6 consecutive quarters
- PBDIT(Q) Highest at Rs 492.75 cr.
- PBT LESS OI(Q) Highest at Rs 350.09 cr.
- PAT(Q) Highest at Rs 258.67 cr.
5
With ROCE of 21.2, it has a Expensive valuation with a 5.1 Enterprise value to Capital Employed
- Over the past year, while the stock has generated a return of 17.88%, its profits have risen by 36%
6
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 2.03% over the previous quarter and collectively hold 9.69% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
7
Market Beating Performance
- The stock has generated a return of 17.88% in the last 1 year, much higher than market (BSE500) returns of 7.71%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Emcure Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Emcure Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Emcure Pharma
17.88%
0.46
39.08%
Sensex
7.07%
0.61
11.53%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.90%
EBIT Growth (5y)
8.80%
EBIT to Interest (avg)
7.55
Debt to EBITDA (avg)
1.10
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
1.28
Tax Ratio
25.84%
Dividend Payout Ratio
0
Pledged Shares
0.04%
Institutional Holding
9.69%
ROCE (avg)
18.86%
ROE (avg)
16.94%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
32
Price to Book Value
6.06
EV to EBIT
21.63
EV to EBITDA
16.72
EV to Capital Employed
5.07
EV to Sales
3.38
PEG Ratio
NA
Dividend Yield
0.20%
ROCE (Latest)
21.25%
ROE (Latest)
16.94%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
PBDIT(Q)
Highest at Rs 492.75 cr.
PBT LESS OI(Q)
Highest at Rs 350.09 cr.
PAT(Q)
Highest at Rs 258.67 cr.
NET SALES(Q)
Highest at Rs 2,363.48 cr
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Operating Profit (PBDIT) - Quarterly
Highest at Rs 492.75 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 350.09 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 258.67 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 2,363.48 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 350.09 cr has Grown at 24.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 280.36 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 258.67 cr has Grown at 28.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 200.88 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
